New drug JY016 targets EGFR-Positive cancers in early trial
NCT ID NCT07510841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called JY016 in people with advanced solid tumors that have a protein called EGFR. The goal is to find a safe dose and see if the drug can shrink tumors. The trial includes people with several cancer types, such as pancreatic, lung, and colorectal cancer, who have not responded to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test predict leukemia risk after cancer therapy?
- Weighted blankets may ease anxiety for cancer patients during IV therapy
- New radiation 'Lattice' method paired with immunotherapy shows promise for tough cancers
- Engineered immune cells take on Hard-to-Treat cancers
- Supercharged immune cells take on solid tumors in early trial
- 600 cancer patients to help unlock secrets of immunotherapy success